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Starting with the discovery of penicillin, the pharmaceutical industry has relied extensively on natural
products (NPs) as an unparalleled source of bioactive small molecules suitable for antibiotic development.
However, the discovery of structurally novel and chemically tractable NPs with suitable pharmacological
properties as antibiotic leads has waned in recent decades. Today, the repetitive ‘‘rediscovery’’ of previously
knownNP classeswith limited antibiotic lead potential dominatesmost industrial efforts. This limited produc-
tivity, exacerbated by the significant financial and resource requirements of such activities, has led to a broad
de-emphasis of NP research by most pharmaceutical companies, including most recently Merck. Here we
review our strategies—both technological and philosophical—in addressing current antifungal discovery
bottlenecks in target identification and validation and how such efforts may improve NP-based antimicrobial
discoveries when aligned with NP screening and dereplication.Bioactive natural products (NPs) and their semisynthetic deriva-
tives have historically provided an unparalleled source of thera-
peutic agents to treat infectious diseases. Indeed, approximately
80% of all available clinically used antibiotics are directly (or indi-
rectly) derived from NPs (Newman et al., 2003). This success
exploits the optimized characteristics of microbial-produced
small molecules, namely their immense chemical diversity,
intrinsic cell permeability, and target specificity versus that typi-
cally reflected in synthetic or combinatorial libraries. NPs reflect
a reservoir of privileged chemical scaffolds which have been
naturally selected by microbes to specifically interact with
a diversity of biological targets in the environment, thereby
providing a fitness advantage to the producing organism. Based
on their target selectivity and intrinsic pharmacological proper-
ties, naturally produced small molecules also serve as critically
important starting points in drug development.Whereas antibac-
terial discovery has yielded over a dozen distinct and clinically
relevant chemical scaffolds (Walsh, 2003), all of which, excluding
oxazolidinones, quinolones, and sulfonamides, are naturally
derived, the breadth of antifungals is noticeably more limited
and represented by only three structural classes, of which two
(polyenes and echinocandins) are naturally derived and the third
(azoles) is synthetic in origin (Ostrosky-Zeichner et al., 2010).
Despite an unmetmedical need formore efficacious antifungal
agents and the seemingly immense opportunity to address this
by discovering novel antifungal leads from natural sources,
a number of technical impediments remain (Koehn and Carter,
2005). Fermentation extracts from microbial cultures are highly
complex mixtures of hundreds (if not thousands) of chemically
uncharacterized components. Screening unfractionated mate-
rials in biochemical assays is therefore complicated by the148 Chemistry & Biology 18, February 25, 2011 ª2011 Elsevier Ltd Aunknown abundance of any target-specific inhibitor relative to
other components in the mixture which can cause nonspecific
inhibition. To address this, diverse chromatographic separation
procedures are available to fractionate extracts; however, their
application in large scale prior to primary assay screening is
both time and resource consuming, particularly when applied
on an industrial scale. Also at issue are the choice of the target
selected, the extent of target validation, and the ease of adapta-
tion to an assay format compatible for high-throughput
screening. Although the full compendium of essential genes in
the model yeast Saccharomyces cerevisiae has been identified
(Winzeler et al., 1999), including orthologous genes in the human
fungal pathogens Candida albicans (Roemer et al., 2003; Becker
et al., 2010) and/or Aspergillus fumigatus (Hu et al., 2007),
whether any individual gene product adapted for target-based
screening is intrinsically ‘‘druggable’’ (i.e., amenable to chemical
intervention) is far from certain (Payne et al., 2007). Finally, an
important consideration in natural product screening is how to
rapidly dereplicate the known and undesirable compounds
from the novel desirable chemical matter suitable for antimicro-
bial lead development.
To address NP-based antimicrobial screening challenges, we
and others have turned to chemical-genetic strategies first
developed in baker’s yeast (Baetz et al., 2004; Giaever et al.,
1999, 2004; Lum et al., 2004) and more recently applied to the
prominent human fungal pathogen C. albicans (Xu et al., 2007,
2009; Rodriguez-Suarez et al., 2007; Jiang et al., 2008). The
overarching principle of this approach relies on a phenomenon
known as chemically induced haploinsufficiency, where deletion
of one allele of the target gene renders the heterozygous deletion
strain hypersensitive to cognate inhibitors of the depleted drugll rights reserved
AB
Figure 1. An Overview of the C. albicans FT
(A) Traditional target-based screening (left) relies
on a somewhat subjective selection of a single
target (dark green circle) among multiple alterna-
tive target choices (light green circles) to screen
against a compound library (blue squares) and
identify a cognate inhibitory lead (red arrow). FT
screening (right) provides a compound-centric
strategy to empirically identify druggable targets.
Further, it provides an unbiased genome-scale,
target-based whole-cell screening approach
(dark green circles; boxed) to more fully link
growth-inhibitory agents to such targets (blue
arrow), including highly validated targets with
promising ‘‘high-value’’ inhibitory lead molecules
(yellow arrow) potentially omitted in single sequen-
tially performed target-based screens.
(B) Individual heterozygote strains contain two
unique barcodes, up (red) and down (blue) tags,
flanked by two pairs of common primer sequences
(black for all the up tags, gray for all the down tags)
at the deleted allele. The FT is composed of either
an 2900 strain pool covering 45% of the
C. albicans genome (the early version we refer to
as FT3K; see Xu et al., 2007) or the present version
described here, containing 5400 heterozygote
strains (FT5K) and representing 90% C. albicans
genome coverage. Aliquots of the pool are treated
with an inhibitory compound or NP extract at
sublethal concentrations or a mock treatment
over 20 population doublings. Provided the inhibi-
tory agent acts through a target-specific MOA and
the corresponding strain(s) is included in the
assay, such strains (highlighted in red) display an
altered growth rate (or fitness, hence the name of the assay) and are specifically depleted from the pool versus the untreated mock control. The relative abun-
dance of each strain is subsequently dereplicated using DNA microarrays competitively hybridized with amplified and labeled barcodes from all strains grown
under the two treatments. The response of each strain to the compound is appraised by a normalized z score, with a positive value indicating hypersensitivity and
a negative value indicating a relative resistance (Xu et al., 2007). As the deleted allele is double barcoded, we selected one of the z scores with the higher absolute
value for each strain in the overall analysis. Multiple experiments were analyzed by hierarchical clustering (cutoff value set at z scores with absolute values greater
than 3.5 in at least two experiments) and results are displayed by heat maps. Shown is an FT profile of brefeldin A and an extract containing this NP, with the
targets (SEC7 and ARF2) and its principal efflux pump highlighted. The gene annotation was based on those that appear in the Candida Genome Database
and consisted of (in this order): strain ID number, orf19 designation,C. albicans gene, andS. cerevisiae homolog. To simplify gene nomenclature, the S. cerevisiae
ortholog name to all C. albicans genes is used throughout the review.
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phenotypes of individual mutants within a defined library of dele-
tion mutants provide important clues as to the drug target and,
therefore, the mechanism of action (MOA) of bioactive
compounds (Leha´r et al., 2008; Smith et al., 2010). Central to
this ‘‘compound-centric’’ approach is the ability to screen bioac-
tive agents across a comprehensive set of potential drug targets,
thereby maximizing the likelihood of linking growth-inhibitory
compounds to their cognate target and in so doing minimizing
the inefficiencies of single, ‘‘target-centric’’ screening, which
immensely restricts the available antimicrobial chemical space
to a single chosen target of interest (Figure 1A). To perform
such analyses comprehensively across a broad drug target set
while using minimal amounts of material, strain-specific barco-
des have been introduced to uniquely identify individual mutants
and facilitate their parallel screening in a coculture (Shoemaker
et al., 1996). Challengedwith a nonlethal concentration of a single
growth-impairing compound or an NP extract mixture, individual
strains displaying an altered fitness (either reduced or enhanced)
within this genetically defined population are identified by micro-
array-basedmethodologies (Figure 1B). Applying this fitness test
approach, essential drug targets can be readily linked to their
cognate inhibitors when screened against a comprehensive
heterozygote deletion mutant strain collection, which could yieldChemistry & Biologadditional mechanistic information regarding drug uptake,
metabolism, off-target activities, and/or export.
Recently, we demonstrated the utility ofC. albicans fitness test
(FT) screening to mechanistically annotate bioactive compo-
nents within crude extracts and identified a new NP structural
class, named parnafungins (Jiang et al., 2008; Parish et al.,
2008; Overy et al., 2009; Adam et al., 2008; Sudhir et al.,
2010). Genetic and biochemical data supported the FT-based
prediction of their MOA as inhibitors of poly(A) polymerase-
mediated mRNA processing (Jiang et al., 2008; Adam et al.,
2008). Parnafungins exhibited potent broad-spectrum micro-
biological activity across medically relevant Candida and
Aspergillus pathogens, were equipotent across existing anti-
fungal drug-resistant Candida spp. (as expected for a new agent
with novel antifungal MOA), and efficacious in a murine model of
disseminated candidiasis—without displaying obvious issues of
cytotoxicity (in vitro) or adverse effects (in vivo) (Jiang et al.,
2008). Thus, parnafungins provide a clear validation of our NP
screening approach to identify new and efficacious NPs with
an unanticipated MOA and novel antifungal lead potential.
Here we review this C. albicans chemical genetics-based NP
screening approach, which was performed at Merck over
a 4 year period, to identify novel target-specific antifungal
molecules potentially suitable for therapeutic development.y 18, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 149
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screening NPs, starting with the isolation of new and diverse
microbial sources and eliciting induction of cryptic secondary
metabolic pathways yielding new bioactive NPs. We also high-
light a unique dereplication strategy to predict the presence of
known or novel bioactive molecules within NP extracts by
coupling LC-MS/FT-MS-based analytical chemistry methodolo-
gies and a reference set of known NPs with MOA annotation
provided by genome-wide FT screening of unfractionated
extracts. Miniaturized, high-throughput separation techniques
based on a range of chromatographic techniques were adopted
to rapidly isolate prioritized NP bioactivities. In illustrating our
approach, we describe the identification and mechanistic char-
acterization of a number of new and known NPs, including aspir-
ochorine and a structurally unique but mechanistically related
Streptomyces metabolite (yefafungin), a novel pentaene NP
predicted to inhibit adenylate cyclase activity and/or cAMP regu-
lation (campafungin), new 1,3-glucan synthase inhibitor analogs
of the ergokonin and papulacandin structural classes, and the
new proteasome inhibitors fellutamides C and D. Moreover, by
integrating these strategies over the screening campaign
exceeding 1800 bioactive extracts, we summarize the chemical
and mechanistic diversity of NPs identified over this time frame,
as well as prominent targets and pathways revealed to be drug-
gable by NPs. In so doing, we share what we have learned
through these efforts and discuss what we believe are significant
issues that continue to impede NP-based antimicrobial
discovery efficiencies.
Antifungal Target Identification and Validation
Pathogenic fungi, especially Candida species, have emerged as
important and prevalent opportunistic pathogens infecting
patients with compromised immunity, including transplant recip-
ients, cancer patients, and those suffering from AIDS (Aperis
et al., 2006). Candida species now account for 8%–9% of all
bloodstream infections, and mortality rates (up to 40%) remain
unacceptably high (Pfaller and Diekema, 2007). Indeed, fungal
infections remain the fourth-leading cause of life-threatening
infections in the hospital setting, and there remains an unmet
medical need for more effective, broad-spectrum antifungal
drugs (Pfaller and Diekema, 2007). Presently, there are only three
classes of marketed antifungal drugs: amphotericin B and its
various formulations that target the cell membrane; azoles
(e.g., fluconazole, itraconazole, posaconazole, and voricona-
zole) that block ergosterol biosynthesis; and echinocandins
(e.g., caspofungin, micafungin, and anidulafungin), which target
cell wall biosynthesis (Ostrosky-Zeichner et al., 2010). However,
each drug class has significant therapeutic limitations, ranging
from toxicity (e.g., amphotericin B and, to a lesser extent, its lipo-
somal formulations) to drug resistance (particularly azoles,
whose clinical use exceeds 20 years) to limited routes of admin-
istration (e.g., echinocandins are restricted to i.v. use only).
To expand the antifungal drug armamentarium, considerable
effort has been directed toward the discovery of new antifungal
targets. As part of this effort, we and others have developed
target validation technologies to extensively survey the
C. albicans genome for essential genes and characterize their
potential as antifungal targets (De Backer et al., 2001; Uhl
et al., 2003; Roemer et al., 2003; Becker et al., 2010). Defining150 Chemistry & Biology 18, February 25, 2011 ª2011 Elsevier Ltd Athe compendium of C. albicans essential genes is warranted,
as C. albicans remains the principal human fungal pathogen,
its genome has been completely sequenced (Jones et al.,
2004) and annotated (Braun et al., 2005), and extensive func-
tional genomic studies in the related but nonpathogenic yeast
S. cerevisiae provide a rational framework for predicting gene
function in C. albicans. However, as C. albicans is an obligatory
diploid, new tools were required to fulfill large-scale functional
analysis of its genome. To this end, we developed a two-step
gene replacement and conditional expression (GRACE) strategy
using PCRmethodologies (Roemer et al., 2003). One allele of the
gene in question was first deleted to construct a heterozygous
deletion mutant, and the expression of the remaining allele was
conditionally controlled by replacing its native promoter with
a tetracycline-regulatable promoter. Importantly, unlike histor-
ical approaches to identifying C. albicans essential genes which
were limited to gene knockout and statistical analyses to infer
essentiality (Noble and Johnson, 2007), the GRACE method-
ology enables direct comparative analysis of phenotypes under
nonrepressing (in the absence of tetracycline) and repressing
(in the presence of tetracycline) conditions. Demonstration of
the GRACE methodology and its large-scale application to
essential gene identification has been performed on approxi-
mately 35% of the C. albicans genome (Roemer et al., 2003).
Importantly, by focusing on suspected orthologs of essential
yeast genes, over 850 C. albicans genes were directly demon-
strated to encode conserved essential functions in the pathogen.
Further, the tetracycline-based conditional repression system
extends to an in vivo infection setting (Rodriguez-Suarez et al.,
2007; Jiang et al., 2008; Xu et al., 2009). To this end, over 100
new antifungal targets have been genetically validated as essen-
tial for establishing and maintaining an acute systemic candidi-
asis infection in immune-competent mice, thereby serving as
suitable prophylaxis and acute infection targets for therapeutic
intervention (Becker et al., 2010).
Extensive target identification and validation have also been
performed in a second principal human fungal pathogen,
A. fumigatus (Hu et al., 2007). Like C. albicans, the A. fumigatus
natural sexual cycle is cryptic and not compatible with perform-
ing classical genetics to identify and validate essential genes
(O’Gorman et al., 2009). As A. fumigatus is naturally haploid,
a one-step promoter replacement strategy was developed in
which a native nitrate-regulatable promoter (pNiiA) was used.
Regulatable gene expression is achieved on nitrate- (inducing)
or ammonium- (repressing) supplemented media and offers
direct assessment of cell viability and terminal growth pheno-
types (Hu et al., 2007). A systematic survey of 54 genes deter-
mined to be essential in yeast and C. albicans (Roemer et al.,
2003) resulted in >70% predicted orthologs sharing an essential
role in A. fumigatus viability. Similarly, this strategy also allows
direct assessment of virulence in an aspergillosis model of
systemic infection, where the in vivo nitrogen levels are suffi-
cient to repress pNiiA (Hu et al., 2007; Rodriguez-Suarez
et al., 2007; Jiang et al., 2008). Numerous independent
large-scale gene deletion studies are also being performed in
C. albicans (Noble et al., 2010) as well as other fungi, including
Cryptococcus neoformans (Liu et al., 2008) and Neurospora
crassa (Collopy et al., 2010). Collectively, these studies provide
an unparalleled clarity to the increasingly broad assortment ofll rights reserved
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tial drug discovery.
C. albicans FT-Based Screening Paradigm
With such an abundance of possible antifungal targets to screen,
the fundamental question is, where to start? Our solution to this
issue was to develop a C. albicans FT-based chemical-genetic
approach to directly screen essentially all potential antifungal
drug targets for cognate inhibitory compounds active against
the pathogen. To facilitate this, we initially constructed 2868
distinct heterozygous deletion strains, each possessing two
independent barcodes to uniquely identify each strain and
facilitate their screening in coculture (Xu et al., 2007). These
strains represent genes of greatest potential as antifungal
targets, as they are (1) experimentally demonstrated as essential
in S. cerevisiae (Winzeler et al., 1999; Giaever et al., 2002) and/or
C. albicans (Roemer et al., 2003), (2) broadly conserved in
A. fumigatus and in many cases demonstrated to be essential
for growth (Hu et al., 2007), and/or (3) suggested to be required
for cell growth based on their strong homology to genes
conserved in metazoans. Initial demonstration of robust MOA
determination by C. albicans FT screening was achieved by
evaluating in the assay a broad collection of known antifungal
compounds of NP or synthetic origin with well-characterized
modes of action (Xu et al., 2007). These included azoles (various
imidazoles and triazoles), amphotericin B, aureobasidin, brefel-
din A, cytochalasin D, cerulenin, nocodazole (and related tubulin
inhibitors), radicicol, tunicamycin, tubercidin, roridin A, verru-
carin A, 5-fluorouracil, and 5-fluorocytosine. In this and subse-
quent studies, themechanistic insights revealed by FT screening
were largely congruent with the published MOAs and/or sup-
ported by independent biochemical and genetic data, which
included important aspects of drug import, efflux, and metabo-
lism (Xu et al., 2007, 2009; Rodriguez-Suarez et al., 2007).
Recently, we have expanded the C. albicans FT to include
5400 double-barcoded heterozygotes (see Tables S1–S3
available online), thus with an 90% genome coverage. This
more extensive platform will more thoroughly identify target-
specific inhibitors which could otherwise be missed in the earlier
version of the assay. More importantly, we have constructed and
included 125 double heterozygous deletion mutants of genes
that are involved in cell wall biosynthesis and display synthetic
lethal genetic interactions between orthologous genes in the
yeast (Lesage et al., 2004). As we describe here, such strains
provide elevated hypersensitivity to cell wall inhibitors and
proved highly effective in identifying both known and new natu-
rally produced 1,3-b-glucan synthase inhibitors.
FT-based screening on a genome-wide scale provides
multiple advantages over traditional target-based screens. First,
the FT facilitates a reverse genetic approach to linking traits
(responses to inhibitory compounds) to preexisting mutations
(heterozygous deletion strains), on a genome scale and directly
in the pathogen. As such, target-based whole-cell assays are
easily developed, scalable, and do not require functional under-
standing of the drug target. Second, drug resistance mecha-
nisms, including drug efflux, permeability, and metabolism, can
be identified early and in parallel to target identification of poten-
tial antifungal agents. Drug targets are also identified empirically
and are biased toward thosewith intrinsic susceptibility to chem-Chemistry & Biological inhibition, and thus are demonstrated to be druggable.
Finally, target validation is performed in key fungal pathogens
only subsequent to the identification of target-inhibitory
compounds. In this way, compound-target pairs can be priori-
tized as antifungal drug leads according to their chemical attri-
butes, the biological process they interdict, and their subsequent
genetic target validation. Thus, a compound-centric focus is
taken, whereby a comprehensive target set is screened across
broad chemical diversity to identify antifungal agents that are
both mechanistically and structurally novel.
C. albicans FT Screening of NP Extracts
Three fundamental issues that impede the efficient screening of
NP extracts include (1) the significant natural products chemistry
isolation and structure elucidation efforts required to identify the
bioactive component within any extract, (2) the need to rapidly
dereplicate known bioactive molecules from those that are novel
early in this process, and (3) the time-consuming exercise of
determining the compound’s MOA. Recently, we and others
have successfully demonstrated how FT profiling of unfractio-
nated NP extracts can address each of these issues (Parsons
et al., 2006; Jiang et al., 2008). We demonstrated the utility of
the FT in mechanistically annotating and identifying target-
specific bioactive compounds within microbial fermentation
extracts that containedwell-characterized bioactive compounds
(Jiang et al., 2008). In nearly all cases, highly diagnostic profiles
were obtained that reflected the purified NP’s known MOA.
Moreover, by constructing a broad reference set of FT profiles
with pure, well-characterized NPs, a comparative analysis
between new/uncharacterized extracts and the compendium
of FT profiles derived from the NP reference set could be used
to predict the presence of novel bioactive compounds within
unfractionated extracts (Herath et al., 2009; Overy et al., 2009;
Ondeyka et al., 2009).
Based on these results, Merck aggressively implemented
a large-scale work plan involving multidisciplinary teams across
multiple research labs to provide microbial-derived extracts for
FT screening as well as all associated follow-up activities
required to identify and purify natural products to a single bioac-
tive component and solve chemical structures of small
molecules predicted to possess both structural and mechanistic
novelty. Over the course of this research program, 1801 NP
extracts with growth-inhibitory activity against C. albicans were
evaluated by FT profiling. This includes 1231 fungal and 570
actinomycete extracts, of which over 770 were derived from
fresh microbial isolates discovered internally to maximize their
taxonomic and geographic diversity (Bills et al., 2009; Collado
et al., 2007) and coupled with nutritional array methodologies
to stimulate normally unexpressed secondary metabolic path-
ways to produce novel bioactive NPs (Bills et al., 2008).
The initial focus of the natural products chemistry groupwas to
rapidly dereplicate knownNPs that were present in the unfractio-
nated extracts. Two approaches were taken to eliminate from
consideration samples that contained known compounds at as
early a stage as possible in this process. The unpurified samples
were analyzed by a standardized LC-MS method in order to
compare all extract components with the Merck historical
database of isolated NPs. By this method, each peak in the
chromatogram could be dereplicated with samples that hady 18, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 151
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from these extracts were compared by LC retention time, the
UV spectrum of the component, and the apparent mass spec-
trum both in positive- and negative-ion modes (Genilloud et al.,
2010). These analyses excluded NPs from subsequent FT
profiling. Accordingly, LC-MS analysis would identify NPs
without consideration for the assigned MOA by FT profiling.
In a more focused second approach, NP dereplication libraries
were constructed based on literature reports of antifungal
components as well as internally discovered compounds with
known MOAs. Each extract was analyzed by high-resolution
(HR) LC-MS, and an ion-extraction algorithmwas used to search
for exact mass data that were consistent with the molecular
weights of the known NPs. In this approach, only the library of
NPs known to inhibit by the MOA obtained by FT profiling was
considered for HR-LC-MS analysis. As this program progressed,
these LC-MS-based dereplication approaches expanded as
additional components could be added both to the internal
Merck NP database as well as to the FT-annotated MOA listings.
Provided that no NPmatch was identified during dereplication
at the extract stage, isolation efforts were prioritized based on
the putative MOA obtained by FT profiling and initiated to sepa-
rate the various components of the crude samples. Chromato-
graphic processing of these extracts was used to identify more
purified materials that maintained the original antifungal activi-
ties. Generally, hydrophobic polymeric resins, silica-based
(reversed or normal phase) resins, countercurrent chromatog-
raphy, and ion-exchange chromatography were used to isolate
a purified component(s) over one or more isolation steps.
Agar-based anti-C. albicans activity was used to rapidly screen
chromatographic fractions for antifungal components. At times,
multiple regions of antifungal activity were identified after chro-
matography. In this situation, FT profiling was used to determine
the region of activity that was related to the desired MOA.
Multiple antifungal components could be related to a family of
NPs or distinct structural classes. Once a purified component
was in hand, the FT profile of this material was related back
directly to that seen with the original extract. Frequently, addi-
tional hypersensitive heterozygote FT strains were present in
the overall profile at the purified component stage, further con-
firming the designated MOA. The isolated compounds were fully
characterized by 1D and 2D NMR spectroscopic methods along
with chemical derivatization when necessary in order to fully
elucidate the structure of all novel antifungal NPs.
In total, over 60 isolation projects were completed in this
screening campaign, identifying numerous novel and known
compounds from this effort (Table 1). A survey of known
target-specific inhibitors identified from this work validates our
approach and reflects (in part) the achievable chemical and
mechanistic diversity of bioactivities that exist in NP extracts.
These include cholesterol-lowering molecules (lovastatin and
hymeglusin), immunomodulators (rapamycin and wortmannin),
and an extensive diversity of 1,3-b-glucan synthase cell wall
inhibitors, from which the therapeutic antifungal agent Cancidas
(commonly named caspofungin) is derived. In addition,
numerous basic research chemical probes commonly used to
study aspects of cellular biology were identified, including inhib-
itors of protein synthesis (sordarin and xylarin), actin cytoskel-
eton (cytochalasins), protein secretion (brefeldin A), fatty acid152 Chemistry & Biology 18, February 25, 2011 ª2011 Elsevier Ltd Abiosynthesis (cerulenin), and mRNA processing (cordycepin).
Importantly, novel NPs with new MOAs of potential antifungal
therapeutic utility were also identified. Below, we describe
a small exemplary set of these compounds identified by
FT-based screening, highlighting both the structural and mech-
anistic diversity of previously unknown bioactive NPs (Figure 2).
Aspirochlorine is a common secondary metabolite produced
by Aspergillus species and is structurally related to the epidithio-
dioxopiperazine class of fungal toxins (Jordan and Cordiner,
1987). Unlike typical mycotoxins, however, aspirochlorine has
been demonstrated to possess remarkable in vitro inhibitory
selectivity toward fungal protein synthesis (C. albicans IC50 =
11 nM) over bacterial or mammalian (>100 mM) protein synthesis
systems (Monti et al., 1999). Aspirochlorine was repeatedly
identified during the course of our work based on a single strain
depletion corresponding to YEF3 (Figure 2B), a fungal-specific
elongation factor of protein synthesis (Sturtevant, 2002).
FT-based screening of aspirochlorine-containing fungal extracts
(and reproduced using pure aspirochlorine) therefore provided
a clear mechanistic profile reflecting the agent’s highly selective
MOA. Cross-referencing FT-MS spectra for the presence of
aspirochlorine among extracts that yielded a YEF3 FT signature
provided robust dereplication of this bioactivity without requiring
chemical isolation. Conversely, FT-MS failed to detect aspiro-
chlorine in a streptomycete extract (ECC729), yielding a related
FT profile with strain depletions corresponding to both YEF3
and SSC1, a mitochondrial heat shock chaperone protein (Fig-
ure 2B). Following bioactivity-guided isolation and structural
elucidation, a novel uridine analog (C26H48N4O13P2; MW
686.63) containing a unique imidodiphosphate linkage and
aliphatic side chain was identified (Figure 3A). The purified
compound demonstrated potent activity against C. albicans
(minimum inhibitory concentration [MIC] = 0.2 mg/ml) and,
consistent with its FT profile, specifically inhibited protein
synthesis in whole cells (Figure 3A). Based on these data, we
have named the compound yefafungin, for yeast elongation
factor affecting fungin.
Whereas the preceding examples highlight relatively simple FT
profiles (e.g., one or two strain depletions reflecting the MOA of
the bioactive NP), often more complex FT profiles were
observed. Such profiles were deemed biologically significant
provided the hypersensitive strains were highly reproducible
over multiple screening replicates and, importantly, there was
a clear functional relationship between those genes correspond-
ing to the heterozygote strain set. One pertinent example is the
fungal extract ECC1977, which produced a complex but repro-
ducible profile spanning the original extract, the predominant
bioactive fraction during isolation, and the purified antifungal
compound (Figures 2A and 2C). After structure elucidation
of this purified component (C25H34O4; MW 398.55), it was
determined to be a new analog of hamigerone (Breinholt
et al., 1997) and, accordingly, named 12-deoxo-hamigerone
(Figure 3B). Despite sharing hypersensitivity of the TUB1 and
TUB2 (to a much less extent) heterozygotes, the overall FT
profiles of 12-deoxo-hamigerone and its original extract were
different from those of benomyl and nocodazole, known inhibi-
tors of microtubule assembly, underscoring difference in chem-
ical structures (and perhaps mechanistic detail) (Figure 2A).
Nevertheless, the significant hypersensitivity of both TUB2 andll rights reserved
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12-deoxo-hamigerone also perturbs microtubule assembly, as
confirmed experimentally in a tubulin in vitro polymerization
assay (Figure3B). Thecompoundwasactiveagainst tubulin-con-
taining eukaryotes (e.g., fungi such asC. albicans [MIC = 4 mg/ml]
and Trichophyton mentagrophytes [MIC = 1 mg/ml]) as well as
multiple mammalian cell lines (IC50 values ranging from 2 to
3 mg/ml), but had minimal appreciable activity against tubulin-
lacking bacteria (e.g., Staphylococcus aureus [MIC > 32 mg/ml]).
More complicated—yet mechanistically significant—FT
profiles can include distinct heterozygote strains displaying
reproducible hyposensitivity (i.e., a fitness advantage and partial
resistance to a bioactive compound) in addition to hypersensi-
tive strains. They collectively provide a unique MOA signature
of a bioactive agent. As exemplified by the fungal-derived NP
extract ECC601 and the purified bioactive compound, their FT
profiles highlighted two prominently hypersensitive heterozygote
strains corresponding to CYR1 (adenylate cyclase) and PRS3
(phosphoribosylpyrophosphate synthetase, which synthesizes
PRPP), as well as two hyposensitive strains heterozygous for
PDE2 (a phosphodiesterase which converts cAMP to AMP)
andBCY1 (the protein kinase A/PKA negative regulatory subunit)
(Figure 2D). Remarkably, the chemical sensitivities of these
heterozygotes were congruent with the functional relationship
between the steps in the cAMP-dependent PKA pathway
(inducing hyphal growth when activated) at which the corre-
sponding gene products are involved, and suggested the bioac-
tive compound affects the cellular cAMP levels. They also raised
the possibility that the synthesis of cAMP is coupledwith transfer
of the pyrophosphate to PRPP, a step likely catalyzed by Prs3p
(Figure 2D). Bioactivity-guided isolation led to the identification
of a novel pentaene-containing compound (C24H30O4; MW
382.50) with its chemical structure shown in Figure 3C. We
name the compound campafungin, for cAMP-affecting fungin.
According to the perceived MOA, campafungin inhibits Cyr1p
and/or Prs3p, and hence the hypersensitivities of both corre-
sponding heterozygous deletions. However, this inhibitory effect
could be partially alleviated if the degradation of cAMP
(by Pde2p) is partially impeded (hence the hyposensitivity of
the corresponding strain), or the inhibitory effect of the regulatory
subunit of the PKA (Bcy1p, to which cAMP binds and thereby
activates the PKA) is quantitatively reduced (hence the hyposen-
sitivity of the BCY1 strain). Consistent with this hypothesis, cam-
pafungin effectively blocked the transition from yeast to hyphae
ofC. albicans (Figure 3C), as did the known PKA inhibitor PKI(11-
22) (Castilla et al., 1998) (data not shown). However, unlike PKI
(11-22), campafungin was partially suppressed by exogenous
cAMP at a concentration near its MIC (200 mg/ml; Figure 3C).
Conversely, for reasons unclear to us, suppression was not
observed at low concentrations (e.g., 100 mg/ml; Figure 3C). As
CYR1 is not essential for viability of C. albicans (Rocha et al.,
2001), our results suggest that Cyr1p is not the direct or only
target of campafungin. The possibility remains that it inhibits
Prs3p, which is essential for viability and hyphal growth (data
not shown). Nevertheless, campafungin is an NP with dual anti-
proliferative and antihyphal activities.
An NP isolated from the actinomycete-derived extract
ECC619 also produced an FT profile in which the MOA was
reflected in both the hypersensitivity and hyposensitivity pheno-Chemistry & Biologtypes of heterozygote strains. Two particularly responsive
strains correspond to DRE2, encoding an essential Fe/S cluster
protein involved in oxidative stress-induced cell death (Vernis
et al., 2009), and DIP5, the dicarboxylic acid permease (Regen-
berg et al., 1998, 1999) (Figure 2E). As predicted by DIP5 hypo-
sensitivity, bioactivity-guided isolation identified a new amino
acid analog (C6H8N2O4; MW 172.14) that we named dretamycin
(dre two amidomycin) (Figure 3D). Consistent with its FT profile,
tetracycline-based repression of DRE2 using the corresponding
GRACE strain produced pronounced hypersensitivity to dreta-
mycin versus control strains as well as marked resistance to
dretamycin in the absence of tetracycline repression (Figure 3D).
This is presumably due to overexpression of DRE2 from the
heterologous tetracycline promoter as compared to its endoge-
nous promoter. Conditional repression of DIP5 also faithfully
reproduced the reduced whole-cell susceptibility to dretamycin
as originally observed in the FT profile. Indeed, dretamycin
import into the cell is likely mediated directly by DIP5, as the
addition of exogenous substrates of this permease (including
L-glutamate and L-aspartate) to the medium noticeably reduces
dretamycin whole-cell inhibitory activity (Figure 3D).
NPs interdicting fungal cell wall processes such as glucan,
chitin, and mannoprotein biosynthesis have long been viewed
as a mechanistically privileged class of bioactive compounds
analogous to the proven efficacy of b-lactam antibiotics. Indeed,
the most recently approved class of antifungal agents (e.g., cas-
pofungin, micafungin, and anidulafungin) represents semisyn-
thetic derivatives of the echinocandin class of NPs. Significant
effort was therefore directed to identifying new bioactivities
targeting fungal cell wall biosynthesis and efficiently dereplicat-
ing novel natural products from those previously known. How-
ever, glucan synthesis inhibitors such as caspofungin do not
elicit a pronounced and mechanistically unambiguous FT profile
corresponding to heterozygote depletions of the 1,3-b-glucan
synthase enzyme complex (Xu et al., 2007), which is composed
of Fks1p (catalytic) and Rho1p (regulatory) subunits. To address
this, double heterozygote mutant strains with elevated hyper-
sensitivity to glucan synthesis inhibitors were constructed and
supplemented to the FT assay. Genes were selected for this
purpose according to their demonstrated mutant phenotype as
either hypersensitive to caspofungin or synthetically lethal in
combination with FKS1 or FKS2 mutations in S. cerevisiae
(Lesage et al., 2004). Therefore, all resulting 125 C. albicans
double heterozygote mutant strains were deleted of one FKS1,
FKS2, RHO1, or PKC1 allele in combination with deletion of
one allele of a second gene (e.g., FKS3, CHS5, or GAS1) re-
ported to genetically interact with the MOA of caspofungin. As
we discuss in a later section, a broad diversity of known NP
inhibitors of 1,3-b-glucan synthase was identified exclusively
from fungal extract sources. New NPs sharing this MOA,
however, were rarely discovered and were restricted to a new
papulacandin analog (ECC3703; C43H56O16; MW 828.90) and
a desulfated ergokonin A analog (ECC3785; C34H53NO7; MW
587.79; Vicente et al., 2001). FT profiles of their corresponding
NP extracts highlight the typical MOA resolution achieved by
including cell wall double heterozygote mutants in the FT assay
(Figure 4).
Whereas NP inhibitors of fungal-specific targets such as Yef3p
and Fks1p provide potential starting points as antifungal leads,y 18, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 153




Active Component(s) IdentifieddECC/Sourcea CaFT Experiment IDb
Natural Products that Have Been Publishede
577/F See reference RNA poly(A) polymerase, RNA cleavage/
polyadenylation complex
Parnafunginf (see Jiang et al., 2008;
Parish et al., 2008)
3552/F See reference Sphingolipid biosynthesis Phomafunginf (see Herath et al., 2009)
3684/F See reference Calmodulin and heat shock response
(CMD1, CMP2, HSP82, SIS1)
Virgineonef (see Ondeyka et al., 2009)
Natural Products that Are Described in Figures 2 and 3 and in Table S1
575/F 1477-3K, 2150-3K Fungal-specific translation initiation factor YEF3 Aspirochlorine (exp. 2531-3K, 2532-3K)
729/A 2387-3K, 2488-3K Fungal-specific translation initiation factor YEF3
(+SSC1)
Yefafunginf (exp. 2969-3K, 2971-3K)
1977/F 3012-3K, 3061-3K Microtubule (TUB1, TUB2, CCT3, CCT8, BUB1) 12-deoxo-hamigeronef (exp. 1497, 2170)
601/F 2154-3K cAMP-dependent protein kinase A pathway Campafunginf (exp. 2544-3K, 2545-3K)
2567/F 222, 286 Proteasome Fellutamides C and Df (exp. 1519, 1767)
619/A 1498-3K, 1499-3K DRE2, DIP5 Dretamycinf (exp. 3115-3K, 3133-3K)
Natural Products that Are Described in Figure 4 and Table S2
Known Glucan Synthase Inhibitors
2406/F 227, 352 FKS1-related cell wall profile Furanocandin
2410/F 314, 315 RHO1, PTP3 in FT3K (ECC1786) Mulundocandin
2430/F 1164, 1211 FKS1-related cell wall profile Papulacandins A and B
3301/F 957, 1148 FKS1-related cell wall profile Pneumocandins
3444/F 297, 308 FKS1-related cell wall profile Ergokonin A
3703/F 1405, 1674 FKS1-related cell wall profile New papulacandin
3785/F 1603, 2174 FKS1-related cell wall profile Novel desulfated ergokonin A
3787/F 1604, 2194 FKS1-related cell wall profile Ascosteroside
3927/F 2003, 2028 FKS1-related cell wall profile Ergokonin B
3979/F 2108, 2109 FKS1-related cell wall profile Arundifungin
4442/A 3476, 3481 Not informative Lydicamycin, 30-demethyllydicamycin
4631/F 3423, 3470 FKS1-related cell wall profile WF11899A
Others
Pureg - Translation elongation factor EF-2 (EFT1) Sordarin (exp. 1252)
3659/F 1225, 1344 Translation elongation factor EF-2 (EFT1) Xylarin
4534/F 3282, 3330 HMG1 Lovastatin
5828/F 4636, 4735 HMG1 Compactin (mevastatin)
3621/A 1170, 1250 TOR complex Rapamycin
3675/A 1352, 1430 TOR complex Wortmannin
3537/A 748, 1477 Sphingolipid biosynthesis Lipoxomycins
3691/F 1437, 2956 Sphingolipid biosynthesis Fumonsins
2922/A 599, 1065 DNA repair Rachelmycin
3447/A 1203, 2535 DNA repair Ravidomycin
3464/A 514, 517 DNA repair Yatakemycin
3445/F 855, 1161 Fatty acid biosynthesis Novel polyacetylene
3871/F 1807 Fatty acid biosynthesis Cerulenin
3728/F 1561, 1658 ERG13, ergosterol biosynthesis Hymeglusin
3755 1550, 1574 ERG24, ergosterol biosynthesis Tyroscherin
Natural Products that Are Described in Table S3
652/F 2232-3K, 2233-3K Phosphoribosyl complex 11-desacetoxyl-wortmannin (exp. 2915-3K)
742/A 2361-3K, 2371-3K Nucleoside analog (NNT1) Toyocamycin
819/A 2413-3K, 2448-3K Distinct complex profile Oxanthromycin (exp. 2978-3K, 2979-3K)
2365/F 3793-3K, 3820-3K ERG25, PDR16, SUB2 PF1163A







Active Component(s) IdentifieddECC/Sourcea CaFT Experiment IDb
2412/F 3251-3K, 3252-3K MEX67 New compoundf
2359/F 155, 178 MCD4, GPI biosynthesis BE-04385A
2556/F 1221, 1350 IMD3, purine de novo synthesis Mycophenolic acid
2662/F 989, 1155 TCA cycle Conocandin (exp. 6268)
3112/F 1165, 1439 FAS1, fatty acid biosynthesis Preussomerins
3232/F 789, 1548 Actin, ACT1, ARP2, ARP3 Cytochalasins
3420/F 465, 1592 SEC7, ARF2, TPO1 Tanzawaic acid G
3423/A 266, 1683 FOL2, folic acid metabolism, C1 pool 7-hydroxylguanine (exp. 4874, 4951)
3474/A 496, 1739 Nucleoside analog, ribosome biogenesis Tubercidin
3489/F 1686, 3286 Signal peptidase complex (IRE1, SPC3, SEC11) New compound,f structurally
from cotransin
3536/F 747, 811 SNF-SWI1 transcription activation complex Borolactin A
3551/F 3806, 3906 Complex, not informative PF1140
3572/F 1082, 1248 RAD52, RFA1, DNA replication Illudin (hydroxybovistol dimer, exp. 6207, 6265)
3689/F 1434, 1435 FKS1, AUR1, complex profile similar
to phomafungin
Lipofungimide (exp. 3542, 3568)
3690/F 1378, 1408 ERG11, NCP1 Restricticin
3715/F 1471, 1537 Zinc homeostasis Hyalodendrin
3721/F 4050, 4051 Nucleoside analog, RNA cleavage, and
polyadenylation complex
Cordycepin
3722/F 1575, 1617 Pyruvate metabolism Conocandin
3920/F 1913, 1960 U3 snoRNP, ribosome biogenesis Homoarginine derivative of 30-aminoadenosine
(exp. 4977, 5213)
4164/F 2681, 2750 ADE8 Preussomerin MB7056B
4662/F 3387, 3733 SEC7, ARF2, CDR1 Brefeldin A
4743/A 3696, 3843 Distinct complex profile TAN1254
4837/A 3797, 3837 ALG7, IAH1, RSB1 Tunicamycin
aMicrobial sources: F, fungus; A, actinomycete.
bUnderlined are the experiments with an early version of Candida albicans Fitness Test (CaFT) (FT3K).
c See Figures 2 and 4 and Tables S1–S3.
d If the isolated compounds were tested in the CaFT, the corresponding experiment numbers are given in parentheses.
e The CaFT results (z scores) are not included in Supplemental Information.
f Novel structures described here or manuscript in preparation.
g Pure compound was used.
Chemistry & Biology
Perspectivebioactive compounds may possess alternative therapeutic
development potential provided their proposed MOA reflects
targets (e.g., Tub1p, Cyr1p) which are conserved in man.
The fungal extract ECC2567 is a case in point. It generated an
FT profile indicative of the proteasome being the target of bioac-
tivity (Figure 2F). The proteasome is a large,multisubunit, proteo-
lytic complex that degrades ubiquinylated proteins to ensure
protein homeostasis and regulation across diverse cellular
processes (Park et al., 2010). Accordingly, the proteasome is
essential for eukaryote cell growth and viability, and inhibitors
of this process, including bortezomib (VELCADE), have been
developed for anticancer therapy (Adams, 2004; Kisselev,
2008). Remarkably, FT profiling of ECC2567 as well as the puri-
fied bioactivity reproducibly identified nine hypersensitive
strains, corresponding to four a (structural) and five b (catalytic)
subunits of the 20S core particle (Figure 2F). Moreover,
ECC2567and its purifiedbioactivity inhibitedproteasomeactivityChemistry & Biologin vitro using aC. albicanswhole-cell extract (Figure 3E), and this
inhibitory activity was reproduced using a human 20S protea-
some assay (data not shown). ECC2567 bioactivity isolation
and structural elucidation revealed two highly related lipopeptide
aldehydes with chemical formulas of C28H51N5O8 (MW 585.37)
and C29H53N5O8 (MW 599.39) and differing only in the C-terminal
amino acid of valine or leucine, respectively (Figure 3E). Based
on their structural similarity to the recently characterized NP pro-
teasome inhibitor fellutamide B (Hines et al., 2008), we named
these new natural products fellutamide C and fellutamide D,
respectively. Considering theirMOA and significantly higher anti-
proliferative activity across multiple human cell lines (IC50 values
range between 0.05 and 1.5 mM) than fungal pathogens (MIC
values of 4–32 mg/ml across Candida spp.), fellutamides C and
D may provide additional chemotherapeutic starting points for
oncology or other recently identified therapeutic applications






Figure 2. FT Profiling of Microbial Fermentation Extracts and Active Compounds Isolated
(A) For each extract (ECC) and compound, two independent fitness test experiments were selected, with the exception of ECC601. The normalized z scores of all
strains in each experiment and the corresponding inhibitory concentration (IC) are listed in Table S1. For those extracts and compounds that were tested in the
FT5K, only strains that were also presented in the 3K version were included in analysis. In the hierarchical clustering (by centroid linkage; Eisen et al., 1998), strains
were selected based on their absolute values of z scoresR 3.5 in at least two FT experiments, with results displayed by heat map. The experiment numbers and
the scale are indicated at the top and at the bottom of the heat map, respectively. Highlighted by yellow boxes and arrows are clusters of heterozygous deletion
strains whose significant hypersensitivity or resistance is indicative of the MOAs of tested extracts and compounds.
(B–F) Clusters of strains that displayed significant hypersensitivity or resistance to specific compounds and the source extracts of aspirochlorine and yefafungin,
both affecting fungal-specific translation factor Yef3p (B), 12-deoxo-hamigerone, a microtubule-perturbing agent (C), campafungin, affecting the cAMP-depen-
dent PKA pathway (D), dretamycin, a Dre2p-affecting amino acid analog requiring the Dip5p dicarboxylic acid permease for cell permeability (E), and fellutamides
C and D, inhibitors of the 26S proteasome (F). The inset in (D) illustrates the part of the cAMP-PKA pathway (highlighted in red and green, for heterozygote hyper-
sensitivity and resistance) that was detected in the fitness test.
Chemistry & Biology
PerspectiveSurveying Target-Specific Chemical Diversity with NP
Extracts from 2005 to 2008
Table 1 summarizes a broad subset of NP crude extracts profiled
in the C. albicans FT that yielded discernable MOAs (with three156 Chemistry & Biology 18, February 25, 2011 ª2011 Elsevier Ltd Aexceptions). In most cases, follow-up HR-LC-MS identified the
known NPs whose targets and/or MOAs were reinforced in the
FT profiles, as indicated by significant and reproducible hyper-
sensitivities of the heterozygotes corresponding to the targets.ll rights reserved
Chemistry & Biology
PerspectiveIn other cases, when HR-LC-MS failed to match the bioactivities
suggested by the FT profiles to any known NPs in our database,
full-scale isolation was promptly initiated. For known NPs, FT
profiles can provide a strong chemical-genetic hypothesis re-
flecting their characterized modes of action, as determined by
significant and reproducible hypersensitivities of strains corre-
sponding to the target genes. For example, lovastatin- or com-
pactin-containing extracts faithfully resulted in hypersensitivity
of the HMG1 heterozygote (Figures 4A and 4F). Similarly, other
known NPs targeting other enzymes of the ergosterol biosyn-
thetic pathway, including hymeglusin (Erg13p; Figures 4A and
4G), restricticins (Erg11p), and PF1163A (Erg25p), were routinely
identified based on the principal depletion of the corresponding
heterozygote strains (Table 1; Table S2). Although theMOA of ty-
roscherin remains uncertain (Tae et al., 2010) it too may interdict
this pathway, as ERG24 (and to a lesser extent, ERG2) heterozy-
gotes were consistently the prominent depletion strains across
multiple fungal extracts dereplicated to contain this natural
product (Figures 4A and 4K). Despite robust demonstration
that the FT correctly identifies each of these mechanistically
distinct—but ergosterol pathway-specific—inhibitors from
crude extracts, structurally novel bioactive compounds that
interdict ergosterol biosynthesis were not discovered.
More broadly, new and previously discovered NPs targeting
a wide range of cellular processes were identified. These include
NPs targeting the biosynthesis of sphingolipids (e.g., lipoxamy-
cins and fumonsins [Figures 4A and 4I], and phomafungin
discovered through our study [Herath et al., 2009]), fatty acids
(e.g., cerulenin and polyacetylenes [Figures 4A and 4H], and
preussomerins), as well as protein synthesis (e.g., xylarin
[Figures 4A and 4E], as well as sordarin [Figure 4E], aspirochlor-
ine [Figure 2B], and at least one novel inhibitor, yefafungin
[Figures 2A, 2B, and 3A]), 30 mRNA processing (e.g., cordycepin
and parnafungins) (Jiang et al., 2008), and rRNA biogenesis
(a new homoarginine derivative of 30-aminoadenosine). More
broadly, additional hits likely targeting nuclear export
(ECC2412), protein translocation in the endoplasmic reticulum
(cotransin and a new lipopeptide derived from ECC3489), target
of rapamycin (TOR) (wortmannin and rapamycin) (Figures 4A and
4D), adenylate cyclase signaling (campafungin) (Figures 2A, 2D,
and 3C), and the new fellutamide inhibitors of the proteasome
(Figures 2A, 2F, and 3E) were also identified by FT profiling.
Importantly, the FT approach ‘‘rediscovered’’ several known
compounds that had not been previously characterized by
past Merck NP discovery efforts (Table 1), reiterating the effi-
ciency of the approach.
NPs which inhibit cell wall biosynthesis have historically
provided an important class from which potential antifungal
drug leads were developed. Therefore, an important and quanti-
fiable measure of our success relates to the diversity of NP inhib-
itors of glucan synthase identified by this project. In addition to
a new papulacandin and a desulfated ergokonin A, a broad
assortment of known echinocandins, pneumocandins, papula-
candins, and acidic terpenoids was discovered (Table 1),
a number of which (corynecandin, fusacandin, furanocandin,
and mulundocandin) had never been previously identified at
Merck. This success was based on the overall work plan as
well as the addition of 125 distinct cell wall double heterozygous
deletion mutants (e.g., fks1/FKS1 gas1/GAS1) corresponding toChemistry & BiologS. cerevisiae orthologs previously demonstrated to possess
synthetic lethal growth effects in combination with fks1, fks2,
or fks3 mutants and/or hypersensitivity to caspofungin (Lesage
et al., 2004). Double mutants encompassing heterozygous dele-
tions of genes involved in both glucan synthase function and
compensatory cell wall processes displayed elevated sensitivity
to glucan synthase inhibitors compared to either single heterozy-
gote. As such, their inclusion served to effectively identify glucan
synthase inhibitors, with FT readouts reflecting extensive sets of
cell wall double heterozygote strains unique to the glucan syn-
thase profile (Figures 4A and 4B; Table S2). In fact, FT profiling
identified glucan synthase inhibitors as the largest single class
of mechanistically characterized bioactive NPs (n = 106), repre-
senting nearly 6% of the 1801 NP extracts screened (Figure 5A).
As none of the above glucan synthase inhibitory NP classes were
identified from actinomycetes extracts (n = 570), we conclude
that secondary metabolism pathways responsible for their
biosynthesis are either unlikely to be conserved in actinomy-
cetes or are not expressed under the conditions used.
Based on the scale and particular sources of NP extracts
examined, we assessed target-selective bioactive hit rates as
well as their prominent targets (and/or interdicting pathway)
and chemical diversity. FT screening ofC. albicans growth-inhib-
itory NP extracts originating within our historical library (n = 673;
572 being fungal derived versus 101 extracts of actinomycetes
origin) resulted in over 140 mechanistically annotated extracts
warranting follow-up activities (Figure 5B). Thus, potential
target-specific bioactive compounds were predicted from FT
profiling at a hit rate of 22%, far exceeding our observed hit
rate for screening synthetic compounds with intrinsic antifungal
activity (data not shown). FT-based screening of an external
(to Merck) historical antifungal NP library for target-based bioac-
tive compounds (n = 306; 260 of fungal origin versus 46 actino-
mycete-derived extracts) also yielded a similarly high hit rate
(28%) to that of our internal historical library. These extremely
high hit rates for target-selective agents within NP extracts likely
reflect the well-accepted view that NPs are selected to provide
highly specific target-modulating activities to benefit the
producing organism. Conversely, target-specific inhibitors are
rarely represented within synthetic compound libraries and
(at best) are either manmade to interdict a small target set or
inadvertently affect unintended targets.
Interestingly, particular cellular processes (e.g., cell wall,
ergosterol, and fatty acid biosynthesis, as well as protein trans-
lation and actin dynamics) were disproportionately affected by
bioactive NPs. In some instances, this likely reflects procedural
biases for those extracts selected for screening or the
nonrandom distribution of metabolic families among microor-
ganisms. For example, roridin and verrucarin NPs are highly
potent and display broad spectrum against C. albicans and
A. fumigatus, as potency was one of the criteria used early on
in the project to prioritize bioactive extracts for FT screening.
However, these compounds are general mycotoxins of consid-
erable toxicity and were not pursued beyond our initial MOA
determination studies during FT profiling which support their
presumed target being eukaryotic initiation factor (eIF) -medi-
ated translation (Xu et al., 2007). In other instances, namely cell
wall/glucan synthase and ergosterol inhibitors, their predomi-





Figure 3. Chemical Structures and MOA Characterization of Representative Natural Products Isolated in This Study
(A) Aspirochlorine and yefafungin. The wild-type C. albicans cultures (in exponential growth) were labeled with [3H]adenine (middle) or [14C]threonine (right) for
40 min in the presence or absence (mock, black squares) of 1 mg/ml yefafungin (red triangles) or aspirochlorine (green triangles). A portion of each culture
was removed at different time points as indicated, and the incorporation of radioactive precursor was then determined. The incorporation of radioactive threonine
was impaired by both aspirochlorine and yefafungin, suggesting inhibition of protein synthesis. Shown are averages of three measurements, with bars indicating
standard deviations.
(B) 12-deoxo-hamigerone. Spot tests were performed as described elsewhere (Xu et al., 2007) with selected heterozygotes at the compound concentrations
indicated. Note that both the TUB1 and TUB2 strains were hypersensitive to 12-deoxo-hamigerone. In vitro microtubule assembly assays were performed




Perspectivebioactive NPs are not generally highly potent and are present in
relatively low titer within crude extracts) and likely reflects their
natural abundance as microbial secondary metabolites.
Although it is possible that this may too reflect a screening
bias, for example the superior resolving power of the FT assay
to robustly identify such mechanisms, this seems an unlikely
explanation because other equally identifiable mechanistic
profiles for other NP classes (e.g., rapamycin, aspirochlorine,
fellutamides, and cordycepin) were identified infrequently.
Based on the apparent predominance of glucan synthase inhib-
itors we identified within bioactive NP extracts as well as their
desirable MOA in targeting cell wall synthesis, one wonders
whether this likely reflects the basis for their early discovery
and advanced development as the most recently marketed
class of NP-derived antifungal agents (Ostrosky-Zeichner
et al., 2010). Interestingly, this observation extends to synthetic
compounds and azole-based antifungal drugs in clinical use.
The most abundant MOA gleaned by FT screening of synthetic
compound libraries (15% of all bioactive synthetic compounds
tested) reveals the azole target ERG11 (plus NCP1 and
CDR1 often represented in the profiles; Xu et al., 2007), and
these cognate inhibitors possess common imidazole or triazole
pharmacophores. Thus, Fks1p and Erg11p appear intrinsically
druggable to abundant NP and synthetic compound classes,
respectively, potentially biasing their predominance as anti-
fungal agents in drug development. Moreover, each of these
antifungal drug classes was discovered and developed
based on their intrinsic microbiological activity including anti-
fungal spectrum and potency, rather than by target-based
screening. In fact, elucidating their drug target and MOA
was only achieved well after their antifungal activities were
discovered. Therefore, an FT-based approach, or analogous
genome-scale screening strategies, are likely required to survey
more broadly the antifungal target space for less prominent
compound/target interactions and from which novel antifungal
leads will be discovered.according to manufacturers’ instructions in the presence of 5 mM paclitaxel, 5 mM
microtubule assembly was completely inhibited by 25 mM 12-deoxo-hamigerone
(C) Campafungin. Wild-type C. albicans cells were grown in RPMI in the absence
examined for hyphal growth using aniline blue staining. At these concentrations,
fungal cells underwent full hyphal growthwith themock treatment (middle). If the c
inhibition at 200 mg/ml campafungin was partially restored (right). However, no su
not shown) was observed. These results suggest that campafungin is both antip
cAMP-PKA pathway. However, it is likely that Cyr1p (the adenylate cyclase) is
experiments, with bars indicating standard deviations.
(D) Dretamycin. Middle: The conditional shut-off strains of DRE2 and DIP5were te
symbols) and repressing (100 mg/ml tetracycline, +TET, closed symbols) conditi
strain, the conditional shut-off strain was exceedingly hypersensitive to dretam
whereas it was resistant under the nonrepressing conditions (likely due to elev
DIP5 strain was resistant to dretamycin when its expression was repressed, con
of dretamycin (against wild-type C. albicans) was increased. However, it was su
not by proline), consistent with the known amino acid substrate specificity of the
of three experiments with coefficient of variation% 15% (not shown). These resu
acid by the cognate transporter Dip5p, and its bioactivity is partially suppressed
(E) Fellutamides C and D. Proteasome assay (Proteasome-Glo; Promega) was
whole-cell extracts prepared from C. albicans grown in the exponential phase. In
compounds were tested at concentrationsR 23MIC, with the exception of lacta
inal bioactive extract eliciting a proteasome-specific FT profile) and lactacystin (a k
albicans. Fellutamide C was tested for dose-dependent inhibition in wild-type C.
whole-cell activity of fellutamide C is largely consistent with inhibition of proteas
assay. Shown are averages of three experiments, with bars indicating standard
See also Table S4.
Chemistry & BiologFollowing the screening of preserved/frozen NP libraries,
significant effort was directed at the isolation of new microbes
(both fungal and actinomycete sources) and preparation of fresh
NP extracts (Bills et al., 2009; Genilloud et al., 2010). Our
reasoning for this was two-fold: (1) only the most stable
secondary metabolites are preserved when frozen over a long
period of time, and thus certain less stable but novel bioactivities
may not be adequately represented; and (2) historical NP
libraries may represent only a limited microbial diversity,
whereas the isolation of fresh microbes biased toward unique
taxonomic and geographic origins may enhance the screening
diversity of secondary metabolites. A summary analysis of
screening 773 such extracts (of which 350 are derived from
fungal sources versus 423 actinomycete-derived extracts) is
provided in Figures 5C and 5D. A similarly high FT profiling hit
rate for mechanistically significant extracts was achieved
(17%) to that of historical/static/frozen NP extract libraries.
This hit rate was again biased toward extracts containing bio-
activities targeting both cell wall and ergosterol biosynthesis.
Two additional NP classes identified were nucleosides (e.g.,
toyocamycin and tubercidin) yielding FT profiles as previously
published (Xu et al., 2007) and DNA-alkylating agents, which
produced dramatic RAD52-based FT profiles, the latter of which
include ravidomycin, rachelmycin, yatekemycin (Figures 4A and
4J), and a new illudin analog, ECC3572 (Table 1). Their common
identification within extracts derived from fresh isolates likely re-
flected a greater microbial bias toward actinomycetes (all but the
illudin analog are actinomycete-derived compounds) than we
previously screened in historical libraries. In fact, nearly half of
all hit extracts were represented in one of these two NP classes
(Figure 5D). Surprisingly, the FT-based mechanism annotation
hit rate among actinomycete extracts was markedly lower (9%)
than that derived from all other screening sources. Moreover,
we frequently encountered complex FT profiles that either
lacked clear MOA insights (e.g., oxanthromycin, antibiotic
TAN1254, or borolactin A) or reflected commonly encounterednocodazole, 2.5 and 25 mM 12-deoxo-hamigerone, or mock treatment. The
.
(mock) or presence of 50, 100, and 200 mg/ml campafungin for 20 hr, and then
no hyphal growth was observed (middle, 100 mg/ml, and data not shown). The
ultures were supplementedwith 10mMexogenous dibutyryl-cAMP, the growth
ppression of campafungin at lower concentrations (100 mg/ml, right; 50 mg/ml,
roliferative and antihyphal, and that the latter activity is mediated through the
not the direct or only target of campafungin. Shown are averages of three
sted for changes in susceptibility to dretamycin under both nonpressing (open
ons. Consistent with the observed hypersensitivity of the DRE2 heterozygote
ycin under a wide range of concentrations under the repressing conditions,
ated expression from the heterologous TET promoter). On the contrary, the
sistent with the FT results. Right: In the minimal medium YNBD, the potency
ppressed partially by (dicarboxylic) amino acids Asp, Asn, Glu, and Gln (but
S. cerevisiae Dip5p permease (Regenberg et al., 1999). Shown are averages
lts suggest that dretamycin is transported into the cell as a dicarboxylic amino
by amino acids that compete for the same permease.
performed according to manufacturer’s instructions with modifications using
the first experiment (middle), the original extract and four additional reference
cystin (without whole-cell activity against C. albicans). Both ECC2567 (the orig-
nown inhibitor of the proteasome) inhibited the in vitro proteasome activity ofC.
albicans and for in vitro proteasome activity (right). The results suggest that the
ome activity. Note that only six concentrations were tested in the proteasome
deviations.








Figure 4. FT Profiling with Double Heterozygote Mutants Effecting
Cell Wall Biosynthesis Robustly Identifies Glucan Synthase
Inhibitors
(A) FT profiles of cell wall-acting bioactive extracts (clusters B and C) and non-
cell wall-acting bioactive extracts (clusters D–K).
(B) FT profiles highlight 27 distinct double heterozygote strains (each deleted
of one copy of FKS1 or RHO1) displaying reproducible hypersensitivity across
ten distinct fungal natural product extracts assayed in two independent
experiments and whose subsequent bioactive elucidation identified known
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Perspectivepolyenes and ionophores that inhibit growth by non-target-
specificMOAs (e.g., disrupting plasmamembrane and ion trans-
port, respectively). We conclude that it strongly appears that
fungal NP extracts are generally more likely to contain target-
specific antifungal bioactivities (as based on clear C. albicans
target-specific FT profiles) than those produced by actinomy-
cetes. This may reflect a potential evolutionary selection for
fungal secondary metabolites to chemically regulate aspects of
fungal metabolism and/or function as growth-inhibitory agents
of competing fungi in a common ecological niche.Concluding Remarks
Despite our expectation that novel and druggable antifungal
leads with unique MOAs, or ‘‘low-hanging fruit,’’ should be
robustly identified through our work plan, such discoveries
proved rare. Why is this the case? Is this an issue of unknowingly
screening a limited microbial diversity despite our best efforts to
address this at the outset? Maybe a more limited biosynthetic
potential exists to produce novel natural products than we
assume from microbiota? We just do not know. However, even
in the rare event when a new leadwas identified, further develop-
ment efforts proved challenging due to significant medicinal
chemistry challenges of optimizing complex NP scaffolds. For
example, parnafungins satisfied all the above requirements,
including intrinsic efficacy of the starting NP (Jiang et al.,
2008), yet essentially all attempted medicinal chemistry modifi-
cations of the NP abolished its activity. Potentially, this may be
addressed by the recent report of a total synthesis of1,3-b-glucan synthesis inhibitors or new analogs thereof (asterisks; see Table
1). Note that double heterozygote cell wall deletion strains are largely unre-
sponsive to non-cell wall-acting bioactive NP extracts. Further, FT profiles
robustly annotate alternative NP extracts containing structurally and mecha-
nistically distinct bioactivities.
(C) A rare cell wall-related FT profile distinct from 1,3-b-glucan synthesis inhib-
itors derived from actinomycete extract ECC4442 and fromwhich lyticamycins
were isolated. Hypersensitive strains correspond to heterozygosity of CTS1,
CHS5, and HOG1, which encode an endochitinase, chitin synthase III compo-
nent, and MAP kinase involved in the high osmolarity stress response, respec-
tively. Note prominent resistance among multiple cell wall mutant heterozy-
gotes, including NCE4 (a negative regulator of CTS1), as well as several
double heterozygote cell wall mutants sharing chitin synthase (CHS3) hetero-
zygosity.
(D) Rapamycin- and wortmannin-containing extracts produce highly related
FT profiles reflecting their known MOA, with TOR1 and the multiple compo-
nents of the TOR complex (KOG1 and LST8) uniquely responsive to these
agents.
(E) Sordarin- and xylarin-containing extracts yielded a target-specific FT
profile with EFT1 heterozygote displaying prominent hypersensitivity (note
that RPS3 and TAF14 heterozygotes contribute to the profile).
(F–I) Lovastatin and compactin, as well as hymeglusin (G), FT profiles capture
their respective drug target, HMG1 and ERG13. NP inhibitors targeting fatty
acid biosynthesis (H; polyacetylenes and cerulenin) or sphingolipid biosyn-
thesis (I; lipoxomycins and fumonsins) prominently affect their known targets,
FAS1 and LCB1, respectively.
(J) FT profiles reflect DNA repair pathways (RAD52, RAD16, RAD7, and RFA1)
among NP extracts containing DNA-alkylating agents, including ravidomycin,
rachelmycin, and yatakemycin.
(K) FT hypersensitivity profile of tyroscherin includes its know target (ERG24)
as well as a complex secondary ‘‘signature.’’ As exemplified by the above
examples, mechanistically distinct FT signatures containing both the drug
target as well as biological pathway/process information provide key mecha-
nistic annotation to warrant follow-up characterization and isolation of bioac-
tivities among NP extracts.
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Figure 5. Summary of FT-Based NP Screening
(A) Summary of identified cell wall-specific NP inhibitors targeting 1,3-b-glucan synthesis. In total, 106 of 1801 (5.9%) NP extracts displaying (1) whole-cell
C. albicans and/or A. fumigatus inhibitory activity and (2) tested in the FT produced profiles highly reflective of a cell wall mechanism of action as 1,3-b-glucan
synthesis inhibitors. The relative frequency of particular glucan synthase inhibitor subclasses is graphically summarized. All but 38 extracts producing this FT
profile were further characterized by UV spectra, retention time, LC-MS/MS, and/or HR-FT-MS to chemically identify the NP inhibitor. The subgroup labeled
‘‘others’’ reflects known glucan synthase inhibitors identified only once during the course of screening.
(B) Summary of NP-based FT profiles identified by screening the corporate historical antifungal NP library. Extracts (673) displaying whole-cellC. albicans and/or
A. fumigatus inhibitory activity were screened within the FT, of which140 extracts (22% hit rate) revealed specific and reproducible strain depletions reflecting
a possible target-specificMOA. Prominent targets (or pathways) reflective of the proposedMOA for bioactive agents aswell as the frequency theywere observed
from this library are indicated. Major mechanistic classes of inhibitory bioactive compounds target cell wall, ergosterol biosynthesis, protein synthesis/translation
initiation (eIF), actin dynamics, and fatty acid biosynthesis. Representative known compoundswithin these subgroups are highlighted. Subgroups labeled ‘‘other’’
and ‘‘unique’’ reflect infrequent hits and those uniquely identified within this historical library, respectively. In cases where neither an NP common name or ECC
number is given, these compounds are absent from Table 1.
(C) A summary of all target-specific NP extracts identified from FT screening using fresh microbial isolates and stimulating secondary metabolism by growth
conditional nutritional arraymethods (Bills et al., 2008). Overall, 773 extracts annotated for displaying whole-cellC. albicans and/or A. fumigatus inhibitory activity
were screenedwithin the FT, of which 129 extracts (17% hit rate) revealed specific and reproducible strain depletions reflecting a possible target-specificMOA.
Major mechanistic classes of inhibitory bioactive compounds target cell wall and ergosterol biosynthesis, followed by nucleoside analogs and DNA-alkylating
agents (likely due to the greater representation of actinomycetes among fresh microbial isolates screened). Note that eIF inhibitors (roridins and verucarrins)
and actin inhibitors (cytochalasins) are not represented in this analysis, because they were easily dereplicated by LC-MS methods following their frequent iden-
tification during screening of the historical antifungal NP library.
(D) Summary of actinomycetes versus fungal-derived target-specific NP extracts identified from FT screening of in-house fresh microbial isolates. Major
mechanistic classes of inhibitory bioactive compounds derived from fungi target cell wall and ergosterol biosynthesis, whereas actinomycetes are biased toward
antifungal metabolites related to nucleoside analogs or DNA-alkylating agents. Note also that the hit rate for target-specific bioactive compounds from actino-
mycetes is <50% seen screening fungal-derived extracts. In part, this reflects the frequent identification of nonspecific growth-inhibitory metabolites (e.g., poly-
enes and ionophores) as well as undesirable modes of action (e.g., mitochondrial respiration inhibitors) common to actinomycetes and which could be effectively
chemically dereplicated (e.g., LC-MS, UV spectra, etc.) and eliminated from FT analysis. As a collaborator’s library yielded similar conclusions as screening our
internal historical NP library (see B), a graphical summary of these results is not included.
Chemistry & Biology
Perspectiveparnafungins A and C (Zhou and Snider, 2010). In other
instances, the starting NP scaffold failed to provide the intrinsic
potency and spectrum necessary to justify exploratory chemistry
resources to optimize their activity. Although such decisions are
undoubtedly subjective, they are inevitable in a pharmaceutical
company setting when choosing how best to invest medicinal
chemistry resources across multiple competing therapeutic
areas. We also conclude that the technological and philosoph-
ical rationale of our approach, although validated, is insufficient
without accompanying innovative advances to expand acces-Chemistry & Biologsible NP diversity for screening. For example, FT-based
screening of NPs challenges historical metrics of screening
throughput: rather than screening a single target across
1,000,000 compounds, thousands of potential targets can be
screened in a single assay against a single extract containing
hundreds of distinct NPs. Despite large-scale FT screening of
NP extracts, we experienced a diminishing return in discovering
novel target-specific inhibitors over time, regardless of the NP
extract source (Figure 5). Our annotation of known and new
target-specific inhibitors identified from fungi proved markedlyy 18, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 161
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Perspectivemore diverse than that obtained from actinomycete sources.
Therefore, an expanding NP screening diversity seems neces-
sary. In part, this may be achieved by considering alternative
NP sources such as plant or marine extracts. Advances in meta-
genomics (Lefevre et al., 2008; Li et al., 2009), novel approaches
to culturing previously unculturable organisms (Kaeberlein et al.,
2002; Lewis et al., 2010; D’Onofrio et al., 2010), or diversity-
oriented synthesis using existing NP scaffolds (Marcaurelle
and Johannes, 2008; Galloway et al., 2009) may also address
this issue. Whether pharmaceutical companies can address
these bottlenecks is also uncertain; hopefully, the biotechnology
industry recognizes the substantial commercial opportunities in
applying a reinvigorated basic research emphasis to these prob-
lems. The importance and increasing role of academic research
facilities (e.g., Broad Institute) and granting institutions (e.g., NIH)
in supporting NP research is also vital. Promoting public-private
partnerships between these institutions and the pharmaceutical
and biotechnology industries may provide an appropriate and
sustainable model, perhaps a public and private consortium,
with the right balance between the necessary scientific innova-
tion and the accompanying financial cost dually required in sup-
porting future NP-based antimicrobial drug discovery efforts.
Indeed, the time for cooperation and collaboration between
basic and industrial NP-based research has never been timelier.SUPPLEMENTAL INFORMATION
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